AOD-9604 in Stödtlen — Fat Loss Peptide Research Guide
AOD-9604 research guide for Stödtlen. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
AOD-9604 won't be found on pharmacy shelves in Stödtlen or anywhere else for that matter — this is a specialist compound supplied via a dedicated online market. This matters because AOD-9604 quality differs enormously across the market — from pharmaceutical-grade 99%+ purity to material with significant impurity issues — and the vendor determines everything about the product. The key verification criteria for AOD-9604 are HPLC purity ≥98%, molecular identity confirmed by mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. Use this guide to evaluate AOD-9604 vendors rigorously — the framework here are universal across all research contexts.
The Science Behind AOD-9604
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Stödtlen comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
How to Source AOD-9604 — Vendor Guide
Quality AOD-9604 sourcing begins with a simple filter: does this vendor make batch-matched COAs available before purchase? Suppliers that publish proactively are operating transparently. Mass spectrometry in the COA confirms that the main HPLC peak is actually AOD-9604 and not a structurally similar impurity — HPLC purity alone cannot verify molecular identity. For Stödtlen researchers evaluating unfamiliar vendors: a modest first purchase to test the product before scaling up your order is what experienced peptide researchers consistently do. Keep lyophilised AOD-9604 at freezer temperature (−20°C) until ready to use; reconstitute only the quantity required for your immediate research and store the rest at −20°C.
Order AOD-9604 — ships to Stödtlen
COA-verified · International tracking · Research grade
Research compound status for AOD-9604 means risk characterisation relies on animal studies, in-vitro work, and limited human observations — rather than the large-scale clinical data that informs approved drug safety. Storage requirements for AOD-9604: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and consumed within 4 weeks; reconstitute only with bac water. Bacterial endotoxin contamination is the most serious safety risk unique to this class of compound — verify endotoxin testing is documented in your batch COA before any injectable research application. Researchers running multi-compound protocols with AOD-9604 should check the research literature for any reported interactions before beginning combination research.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.